Black Diamond Therapeutics, Inc. (BDTX) stock
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.44−0.09 (-5.88%)
Close on Nov 17, 2026Market cap $82.73MP/E –Yield –
Black Diamond Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Black Diamond Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $70.00M. The highest annual figure on record is $70.00M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.00M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2020 | Dec 31, 2020 | $0 | – |
| FY2019 | Dec 31, 2019 | $0 | – |
| FY2018 | Dec 31, 2018 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $70.00M | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
See a number that looks wrong?